In order to explore potent derivatives of pradimicins (PRMs), modification of their C4'-amino group was carried out. 4'-7V-Cyano (1, 2), 4'-deamino-4'-nitroguanidino (4), 4'-deamino-4'-ureido (7~9) and 4'-deamino-4'-thioureido (10) derivatives were synthesized by trimethylsilylation of PRMs A and C, followed by condensation with appropriate reagents. 4'-Deamino-4'-guanidino (5) and 4'-deamino-4'-amidino (6) derivatives were synthesized by catalytic hydrogenation of 4 and 2, respectively. 4'-7V-Nitroso derivative 3 was prepared by treatment of PRMA with nitrous acid. Amongthese compounds, the 4'-7V-cyano derivative of PRMC (2) exhibited in vitro and in vivo antifungal activities comparable to the parent compoundstogether with good water-solubility.
The pradimicins (PRMs) are a new family of antibiotics ( Fig. I )1"5* that exhibited broad-spectrum antifungal activity both in vitro and in vivo studies. Although they are relatively nontoxic, their limited water-solubility due to amphoteric nature hampered further development studies. Thus, we initiated chemical modification of PRMsfocused on the C4'-position6~8) in order to improve water-solubility. In the previous paper8), we reported water-soluble 4'-AT-alkyl and -acyl and 4'-deamino-4'-hydroxy PRM derivatives. This report describes the syntheses and antifungal activities of the other 4'-amino-modifIed PRM derivatives; 4' -7V-cyano, 4' -7V-nitroso, 4' -guanidino, 4' -amidino, 4' -ureido and 4' -thioureido derivatives. 
Synthesis
PRMsA and C have many functional groups that mayinterfere with substitution of the 4'-amino group. In the previous paper3), we reported 4'-7V-alkylation and -acylation of PRMs, with alkyl halides and activated carboxylic acids respectively, proceed smoothly in the presence of N,Obis(trimethylsilyl)acetamide (BSA) . N-Substitution ofPRMs with the other reagents also went smoothly.
Thus, the BSA-pretreated PRMsA and C were reacted with cyanogen bromide in dichloromethane at room temperature, followed by detrimethylsilylation with HCl-MeOH afforded the 4'-N-cyano derivatives, 1 and 2, respectively, in good yields. The
Correspondence should be addressed to Jun Okumura, Britsol-Myers Squibb Research Institute, 2-9-3 Shimomeguro, Meguro-ku, Tokyo 153, Japan. TV-unsubstituted cyanoamino derivative 2 was rather unstable in acidic media to give the 4'-ureido derivative 7, while the iV-methylcyanoamino derivative 1 was stable in the same conditions. In a similar way to 1 and 2, BSA-pretreated PRMA was reacted with methyl isocyanate and methyl isothiocyanate to afford the 4'-dimethylureido derivative (9) and 4'-dimethylthioureido derivative (10),
respectively. PRMsA and C were reacted with trichloroacetyl isocyanate in a similar way, followed by alkaline hydrolysis, to give the 4' -ureido (7) and the 4' -monomethylureido (8) derivatives, respectively.
The reaction of BSA-treated PRMC with JV-nitro-S-methylisothiourea required more severe conditions.
It proceeded in DMFat high temperature (80°C for 2 hours) to give the 4/-nitroguanidino derivative 4, which was subjected to catalytic hydrogenation to afford the 4'-guanidino derivative 5. Catalytic hydrogenation of the 4'-iV-cyano derivative 2 in aqueous acetic acid afforded the 4'-amidino derivative 6, together with the 4'-ureido derivative 7, which was considered to be derived from 2 by action of acetic acid. PRMA was treated with sodium nitrite in aqueous acetic acid to give the 4'-nitrosoamino derivative 3.
In Vitro Activity The antifungal activity was determined by the 2-fold agar dilution method on yeast morphology agar buffered with 0.067m phosphate, pH 7.0 and the results are summarized in Table 1 . The 4'-7V-cyano derivative 2 showed improved antifungal activity against Candida albicans and Candida tropicalis and retained antifungal activity of the parent PRMC against Cryptococcus neoformans and Aspergillusfumigatus, while the 4'-iV-methylcyano derivative 1 was moderately active against A. fumigatus although the activity against the yeasts was very similar to 2. The 4'-Ar-nitroso (3) and 4'-nitroguanidino (4) derivatives also showed improved antifungal activity against C. tropicalis with retention of activity against all the other strains as compared with PRMs A and C. On the contrary, the 4'-guanidino (5) and 4'-amidino (6) derivatives showed no activity against C. tropicalis at 100/ig/ml with retention of the activity against the other strains. The 4'-ureido derivative 7 was active against only yeasts and the other TV-substituted ureido or thioureido derivatives (8~10) showed no activity against A. fumigatus. Among the C4'-amino-modined derivatives, the derivatives 1 through 4 retain in vitro activity ofPRMs, but the 4'-ureido and 4'-thioureido derivatives, 7 through 10, lose activity against A. fumigatus.
In Vivo Activity and Water-solubility of the 4'-A^-Cyano Derivative 2 AUG. 1993 showed broader in vitro antifungal spectrum than PRMsA and C was determined in mice infected with C. albicans A9540 and A. fumigatus IAM2034 after intravenous administration, and the results are summarized in Table 2 . All of the compounds were as effective as PRMsA and C against C. albicans A9540. However, against A. fumigatus IAM2034, only compound 2 was as effective as PRMA among these compounds.
The water solubility of 2 was more than 20 mg/ml in phosphate-buffered saline containing Ca2 + and Mg2+at pH 7.27). Due to the electron withdrawing property of the cyano group, the basicity of 4'-amino group of 2 is thought to be much lower than the parent antibiotic resulting in the improvement of its water-solubility at a neutral pH. In summary, among the 4'-amino-modified derivatives of PRMsA and C synthesized in this study, the 4'-7V-cyano PRMC (2) shows antifungal activity comparable to the PRMsboth in vitro and in vivo together with high water-solubility.
Experimental
MPswere determined using a Yanagimoto micro hot-stage apparatus and are uncorrected. NMR spectra were recorded on a JEOL GX-400 (400 MHz). Mass spectra were recorded on a JEOL JMS-AX505H (FAB) mass spectrometer. Synthesis 4'-iV-Cyano Derivatives (1 and 2) Cyanogen bromide (180mg, 1.7mmol) was added to a mixture ofPRM C (67mg, 0.081 mmol) and BSA (0.5ml, 2.02mmol) in dichloromethane (2ml) and the mixture was stirred overnight at room temperature. After removal of the solvent, MeOH(2ml) and In HC1 (1 ml) was added and the mixture was chromatographed on a column of Cosmosil 75C18-OPN (Nacalai Tesque, Inc., 100 g). The column was eluted with water and 10~40%acetonitrile successively. The eluate was collected in fractions, which were monitored by HPLC. The fractions containing 2 were combined, concentrated in vacuo and freeze-dried to give 48mg (79%) ofa light red amorphous powder. 4'-7V-Nitroso Derivative (3) Sodium nitrite (1 m aqueous solution, 0.5ml) was added dropwise to a stirred solution of PRMA (100mg, 1.19mmol) in 0.25m aqueous acetic acid (10ml). The mixture was stirred for 2 hours at room temperature.
By a similar purification to 2, 75mg (72%) of 3 was obtained. MP 230~240°C (dec); IR vmax (KBr) cm"1 1720, 1600, 1450, 1295, 1160, 1060; Mass (FAB) m/z 870 (M+H)+; UV Xmax (1/100n NaOH) nm (e) 320 (14,100), 498 (14,000); XH NMR (DMSO-d6) 3 0.98 (3H, d, /=7Hz, 5'-CH3), 1.33 4'-Nitroguanidino Derivative (4) iV-Nitro-S-methylisothiourea (150mg, 1.14mmol) was added to a mixture of PRMA (100mg, 1.21 mmol) and BSA (0.5ml, 2.02mmol) in DMF (2ml) and the mixture was heated at 80°C for 2 hours. After removal of the solvent, MeOH(2ml) and 1 n HC1 (1 ml) was added and the mixture was purified by a similar way to that of compound 2 to give 69mg (63%) of4. MP 220~230°C (dec); IR vmax (KBr) cm"1 1720, 1600 , 1290 , 1160 , 1050 Mass (FAB) 4'-Guanidino PRM C (5)
A mixture of4 (50mg, 0.055mmol) and 10% palladium on charcoal (20mg) in 1 n HC1-MeOH(1 : 10, 5 ml) was hydrogenated overnight under atmospheric pressure. The mixture was chromatographed on a column of Cosmosil 75C18-OPN (Nacalai Tesque, Inc., 100 g) eluting with water and then with 1/1,000n hydrochloric acid -acetonitrile (80 : 20~60 : 40) 
4'-Ureido
PRMs (7-9) and 4'-Thioureido PRM (10) Trichloroacetyl isocyanate (316mg, 1.7mmol) was added to a mixture ofPRMC (85 mg, 0.102mmol) and BSA(0.5ml, 2.02mmol) in dichloromethane (2ml) and the mixture was stirred overnight at room Susceptibility Testing MICs were determined on yeasts morphology agar (YMA, Difco Laboratories, Detroit, Mich., U.S.A.) buffered with 0.067m phosphate, pH 7.0. Nine parts of molten agar were combined with one part of antibiotic dilution petri dishes. A 5-^1 suspension containing 2 x 106 cells per ml was spotted on the surface of the agar plates. The plates were incubated at 28°C for 60 hours. MICswere recorded after 40 hours of incubation and defined as the lowest antibiotic concentrations showing no growth or less than five discrete colonies per spot.
Experimental Infection in Mice
Groups of 5 male ICR mice weighing 20~24g at each dose level received 10-LD50 of C. albicans A9540 or A.fumigatus IAM2034 intravenously and test compounds given intravenously once immediately after the infection. The 50% protective dose (PD50) was calculated by the method of Litchfield and Wilcoxon9) from the survival rate 20 days after the fungal infection.
